Document Detail

Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence.
MedLine Citation:
PMID:  17888616     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Therapeutic adherence determines the efficacy of treatments in the clinical practice. Especially in chronic asymptomatic diseases large differences exist between therapeutic success in clinical studies and clinical practice. The treatment of osteoporosis using bisphosphonates is considerably influenced by the low adherence of patients due to the complicated drug application. SUBJECTS AND METHODS: The VIVA study analyzed the preferences of 1635 patients with osteoporosis in Slovakia using a simple questionnaire. RESULTS: The majority of patients--76% preferred the monthly regime of bisphosphonate therapy, 22% of patients preferred the weekly regimen and only a minority--2% preferred daily application. CONCLUSION: The results are in agreement with results of the BALTO study in the USA and the SWIFT study in Switzerland showing a clear preference to the monthly regime. The preferences of patients were motivated by various different aspects of improved quality of life, which is offered by the new bisphosphonate regimen once monthly.
Juraj Payer; Zdenko Killinger; Ivana Sulková; Peter Celec
Related Documents :
7632216 - Why do so few patients appeal against detention under section 2 of the mental health act?
17190666 - Prospective patient and physician preferences for stimulation or no stimulation in ivf.
25298946 - Sub mucous cleft palate with fenestration.
21126886 - Vasopressin deficiency and vasodilatory state in end-stage liver disease.
9367326 - Mr findings in hereditary isolated growth hormone deficiency.
25056376 - Pre-flight assessment in patients with obesity hypoventilation syndrome.
Publication Detail:
Type:  Journal Article     Date:  2007-08-09
Journal Detail:
Title:  Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie     Volume:  62     ISSN:  0753-3322     ISO Abbreviation:  Biomed. Pharmacother.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-15     Completed Date:  2008-06-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8213295     Medline TA:  Biomed Pharmacother     Country:  France    
Other Details:
Languages:  eng     Pagination:  122-4     Citation Subset:  IM    
5th Department of Internal Medicine, Faculty Hospital, Comenius University, Bratislava, Slovakia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Bone Density Conservation Agents / administration & dosage*
Diphosphonates / administration & dosage*
Drug Administration Schedule
Middle Aged
Osteoporosis / drug therapy*
Patient Compliance*
Patient Satisfaction / statistics & numerical data
Quality of Life
Reg. No./Substance:
0/Bone Density Conservation Agents; 0/Diphosphonates

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hyperglycemic condition disturbs the proliferation and cell death of neural progenitors in mouse emb...
Next Document:  Antifungal canthin-6-one series accumulate in lipid droplets and affect fatty acid metabolism in Sac...